Pitolisant protects mice chronically treated with corticosterone from some behavioral but not metabolic changes in corticosterone-induced depression model.

摘要: Abstract Purpose Histamine H3 receptor ligands may have antidepressant and anxiolytic effects. They can also compensate for metabolic disorders, which affect glucose or triglyceride levels. In previous studies, we shown that pitolisant, a histamine antagonist/inverse agonist σ1 agonist, prevented the development of certain depressive-like disorders in mice been treated chronically with olanzapine. Methods As continuation our experiments, this study aimed to investigate antidepressant- anxiolytic-like activity pitolisant using corticosterone-induced depression model. The forced swim elevated plus maze tests were used as behavioral endpoints. We studied effect had on level acetoacetic acid urine well tolerance body weight administered corticosterone. Results Pitolisant (10 mg/kg b.w.) did not prevent behavior during chronic corticosterone administration but counteract anxiety-like behavior, whilst fluoxetine (10 mg/kg) was protect from both these behaviors. None treatments showed an locomotor mice. increase levels urine, nor it improve tested Conclusion Although literature data indicates there is significant potential finding anti-diabetic drug among ligands, study, only slightly abnormalities. However, further research will be required pitolisant's activity.